(PRNewsfoto/BioHarvest Sciences Inc.)

NR: 1-071521

  • First biotechnology company engaged in the production of Cannabis biomass and cannabinoids to publish an ESG report and commit to tangible, science-based targets
  • BioFarming manufacturing process uses 99.99% less land than traditional outdoor agriculture, while generating no direct greenhouse gases "GHG" emissions, no hazardous waste, and producing 100% biodegradable wastewater
  • Committed to further reducing its environmental footprint while scaling production
  • Directly supports four United Nations Sustainable Development Goals

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) today announces the publication of its inaugural Environmental, Social, and Governance (ESG) Report, detailing the Company's performance and ongoing commitment to creating a sustainable future. BioHarvest is the first biotechnology company engaged in the production of Cannabis and cannabinoids to publish a comprehensive ESG report that commits to meaningful science-based targets over the next five years.

Sustainability has always been at the core of BioHarvest, with the Company's BioFarming technology allowing it to produce active plant ingredients without having to grow the plant itself. This practice substantially reduces resource requirement in general, as well as greenhouse gas emissions - which would otherwise be generated - and prevents biodiversity loss. For example, the Company:

  • Uses 99.99% less land than traditional agriculture
  • Produces zero Scope 1 or direct GHG emissions in the BioFarming manufacturing process
  • Uses no solvents or pesticides in the manufacturing process, resulting in wastewater that is 100% biodegradable and contains no chemicals
  • Produces no hazardous waste in the BioFarming manufacturing process

The report details the policies, metrics, and programs that support each of the Company's four key ESG pillars:

  1. Product: Promoting pure well-being by providing fully traceable, science-based and innovative products with proven health benefits that improve the well-being of our customers.
  2. Process: Demonstrating the minimal footprint of our production process while striving to reduce any adverse impact on water use, climate, and the environment.
  3. People: Supporting our people by treating them with the utmost respect, the safest working conditions and allowing them to develop and thrive in the workplace; and
  4. Governance: Setting the standard for end-to-end sustainability, ethical marketing, business ethics, and transparency in our industry.

The report is aligned with the United Nations Sustainable Development Goals and the reporting requirements of the Task Force on Climate-Related Financial Disclosures and the Sustainability Accounting Standards Board.

While the report primarily focuses on the production of VINIA® (see: ),  it provides important insights on how that production process can transform global Cannabis production. The Company recently announced a significant breakthrough ( See News Release dated July 7, 2021 ) in its production of Cannabis and is on track to reach commercialisation in H1 2022. The sustainability advantages which will accrue from the Cannabis vertical, will be benchmarked versus the industry and highlighted in the Company's 2022 sustainability report.

" I could not be more excited to release our inaugural ESG report and share the incredible progress we have made over the past 10 years to help create a more sustainable future. Unlike other companies, sustainability is not something we feel compelled to support; to the contrary, it is at the core of our technology, which unlocks the cellular biological secrets of the plant kingdom, " said Ilan Sobel , CEO of BioHarvest Sciences. " As the company grows, we want to redouble our efforts to ensure that our transparency, governance, environmental and social record remains best-in-class for the nutraceutical and cannabis industries as well as future verticals we expand into with our BioFarming technology."

Eitan Popper , Chairman of BioHarvest's Board of Advisors, and co-founder and previous President of MedReleaf, added, "Based on my knowledge of the industry , BioHarvest is currently the only Company in the Cannabis sector, that is effectively pursuing a sustainability agenda through its core technology. " Mr. Popper also highlighted the reduced energy related impact when it comes to Cannabis production: "A large portion of North America's Cannabis production capacity is based on indoor cultivation, which is extremely energy intensive, and represents a major challenge as the industry continues to grow. BioHarvest's process will require substantially less energy when compared to both indoor and greenhouse Cannabis production. Ultimately, this doesn't only reduce the per gram CO2 footprint by a few orders of magnitude, it obviously also reduces the cost".

To download a copy of the ESG report , please visit:

About BioHarvest Sciences Inc.

Based in Vancouver , BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to also become a leading supplier of Cannabis for both medicinal and legal recreational purposes. For more information visit: .

BioHarvest Sciences Inc.
Ilan Sobel , Chief Executive Officer

Twitter , Facebook , LinkedIn , YouTube

Forward-Looking Statements

Information set forth in this news release includes might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance our production method will meet its potential of transforming Cannabis production or that we will be able to commercialize our first Cannabis products in the first half of 2022. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the Company is in the process of constructing a two-ton production facility the Company's current licensing only permits scientific research. Projected sales of Cannabis will require the Company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:

SOURCE BioHarvest Sciences Inc.

Cision View original content to download multimedia:

News Provided by Canada Newswire via QuoteMedia


BioHarvest Sciences

Keep reading...Show less


Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer

No Approved Treatment Options Available to Patients in Third-line Setting

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less


First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation

Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE ® Therapy in Small Cell Lung Cancer

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Boosh Settles $190,000 In Debt

Boosh Settles $190,000 In Debt

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") announces that it has entered into a settlement agreement with an arm's length third party for the settlement of $191,428.52 in debt for services previously provided through the issuance of 1,519,274 common shares at a deemed price of $$0.126 per share.

All securities issued in the debt settlement are subject to a four month and one day hold period expiring on December 04, 2022.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less


Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include:

  • Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, resulting from 3% growth in global product sales partially offset by lower Other Revenue from our COVID-19 manufacturing collaboration.
    • Volumes grew double-digits for a number of products including Repatha ® (evolocumab), Prolia ® (denosumab), LUMAKRAS ® /LUMYKRAS™ (sotorasib) and EVENITY ® (romosozumab-aqqg).
  • GAAP earnings per share (EPS) increased from $0.81 to $2.45 driven by a decrease in operating expenses due to the write-off of $1.5 billion in Acquired In-Process Research & Development (Acquired IPR&D) associated with our acquisition of Five Prime Therapeutics in Q2 2021 and lower weighted-average shares outstanding in Q2 2022, partially offset by an impairment charge related to the divestiture of GENSENTA, a generics subsidiary in Turkey .
    • GAAP operating income increased from $0.8 billion to $2.2 billion , and GAAP operating margin increased 21.1 percentage points to 34.6%.
  • Non-GAAP EPS increased from $1.77 to $4.65 driven by a decrease in operating expenses due to the write-off of $1.5 billion in Acquired IPR&D associated with our acquisition of Five Prime Therapeutics in Q2 2021 and lower weighted-average shares outstanding in Q2 2022.
    • Non-GAAP operating income increased from $1.6 billion to $3.3 billion , and non-GAAP operating margin increased 26.8 percentage points to 53.1%.
  • The Company generated $1.7 billion of free cash flow for the second quarter versus $1.7 billion in the second quarter of 2021.
  • 2022 total revenues guidance revised to $25.5 - $26.4 billion ; EPS guidance revised to $11.01 - $12.15 on a GAAP basis, and reaffirmed at $17.00 - $18.00 on a non-GAAP basis.

"We are focused on delivering our long-term objectives by serving an ever-increasing number of patients around the world with our medicines," said Robert A. Bradway , chairman and chief executive officer. "We are advancing our pipeline and look forward to important readouts over the next few months."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
The Gummy Project Secures Additional Repeat Order from Existing Customer Flair Airlines

The Gummy Project Secures Additional Repeat Order from Existing Customer Flair Airlines

  • The Company had previously announced its first repeat order with existing customer Bard on the Beach.
  • Partnership with Flair rapidly accelerates The Gummy Project's growth across Canada with GUMY products being featured for sale on all Flair flights.
  • As the "Better for You" gummy company, The Gummy Project, through its Flair Airlines partnership, will extend the reach and effectiveness of its purpose driven mission to support endangered keystone species.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce that the Company has received a repeat order from its existing customer Flair Airlines ("Flair").

"We are very pleased to receive our second repeat order from an existing customer. We view this as another vote of confidence that our customers are very much enjoying our gummies and strongly embracing our mandate to support endangered keystone species," said Charlie Lamb, President & CEO of The Company. "We look forward to building upon the momentum that the Company has created as we continue to accelerate revenue generation and brand awareness."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Gilead Sciences to Acquire MiroBio

Acquisition Provides Gilead with MiroBio's Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform –

– MiroBio's Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead's Inflammation Research and Development Strategy –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News